Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma's stock price has been impacted by several significant events in the past six months, with a notable -72.71% change over this period. On April 3, 2026, Matinas BioPharma received a notice from NYSE American indicating non-compliance with continued listing standards. On March 31, 2026, the company announced staff reductions and is seeking a partner for MAT2203. On January 23, 2026, Jerome D. Jabbour was appointed interim Chief Financial Officer. On December 12, 2025, Matinas BioPharma amended its CEO contract to include extended change-in-control bonus protections. On November 21, 2025, the company announced a planned CFO departure. On March 11, 2025, February 13, 2025, and February 7, 2025, Matinas BioPharma announced the appointment of seasoned biotech leaders and new members to its Board of Directors, including an Audit Committee Chair.

As a clinical-stage biopharmaceutical company, Matinas BioPharma Holdings, Inc. does not have traditional product or service demand seasonality in the commercial sense. The company's revenue generation is not tied to seasonal consumer purchasing patterns. Instead, its progress and financial needs are more influenced by the cyclical nature of clinical trials, regulatory milestones, and funding rounds, which do not typically follow a predictable seasonal pattern.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies using its proprietary lipid nanocrystal (LNC) platform delivery technology. The company operates within the Healthcare sector, specifically in the Biotechnology & Drugs industry. Its core business revolves around its LNC platform, which is designed to improve the intracellular delivery of small molecules and oligonucleotides, aiming to make therapeutics safer, less toxic, more tolerable, and orally bioavailable. Its major product candidates include MAT2203, an oral formulation of amphotericin B, and MAT2501, an orally administered formulation of amikacin. The company is also pursuing additional discovery programs directed at oncology and inflammation, leveraging its LNC platform. Matinas BioPharma has collaborations with entities like the National Institute of Allergy and Infectious Diseases, BioNTech SE, and Genentech Inc.

Matinas BioPharma Holdings, Inc. is based in Bedminster, New Jersey, United States. As a clinical-stage company, its primary operations and development activities are centered in this location.

Matinas BioPharma's brand reputation in the past year has likely been subject to mixed influences. Positive developments include the announcement of positive in vivo safety data for its oral LNC-Docetaxel formulation in March 2026, and the appointment of experienced biotech leaders to its Board of Directors in early 2025. However, the recent notice of non-compliance with NYSE American listing standards in April 2026, coupled with multi-year losses and an auditor's report raising substantial doubt about the company's ability to continue as a going concern, could significantly impact its reputation negatively among investors and partners. The news of staff reductions and seeking a partner for MAT2203 in March 2026 also suggests financial challenges and strategic shifts that could be perceived as unfavorable.

The ownership structure of Matinas BioPharma (MTNB) is a mix of institutional, insider, and retail investors. Approximately 1.43% to 7.75% of the company's stock is held by institutional investors, while insiders hold around 11.5% to 32.75%, and retail investors own a significant portion, ranging from 67.25% to 83.51%. Major institutional owners include Citadel Advisors Llc, Vanguard Group Inc, and Geode Capital Management, Llc. Among individual insider shareholders, Jerome D. Jabbour (President and CEO) is noted as owning a substantial number of shares.